Literature DB >> 22982190

Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

Elena Sebastián1, Miguel Alcoceba, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, David González, M Eugenia Sarasquete, M Carmen Chillón, Noemí Puig, Rocío Corral, Emilia Pardal, Alejandro Martín, Eva González-Barca, M Dolores Caballero, Jesús F San Miguel, Ramón García-Sanz, Marcos González.   

Abstract

The pathogenesis of diffuse large B-cell lymphoma (DLBCL) remains partially unknown. The analysis of the B-cell receptor of the malignant cells could contribute to a better understanding of the DLBCL biology. We studied the molecular features of the immunoglobulin heavy chain (IGH) rearrangements in 165 patients diagnosed with DLBCL not otherwise specified. Clonal IGH rearrangements were amplified according to the BIOMED-2 protocol and PCR products were sequenced directly. We also analyzed the criteria for stereotyped patterns in all complete IGHV-IGHD-IGHJ (V-D-J) sequences. Complete V-D-J rearrangements were identified in 130 of 165 patients. Most cases (89%) were highly mutated, but 12 sequences were truly unmutated or minimally mutated. Three genes, IGHV4-34, IGHV3-23, and IGHV4-39, accounted for one third of the whole cohort, including an overrepresentation of IGHV4-34 (15.5% overall). Interestingly, all IGHV4-34 rearrangements and all unmutated sequences belonged to the nongerminal center B-cell-like (non-GCB) subtype. Overall, we found three cases following the current criteria for stereotyped heavy chain VH CDR3 sequences, two of them belonging to subsets previously described in CLL. IGHV gene repertoire is remarkably biased, implying an antigen-driven origin in DLBCL. The particular features in the sequence of the immunoglobulins suggest the existence of particular subgroups within the non-GCB subtype.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982190     DOI: 10.1016/j.ajpath.2012.07.028

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell.

Authors:  Agnieszka Malecka; Anne Tierens; Ingunn Østlie; Roland Schmitz; Gunhild Trøen; Signe Spetalen; Louis M Staudt; Erlend Smeland; Harald Holte; Jan Delabie
Journal:  Haematologica       Date:  2015-05-22       Impact factor: 9.941

Review 2.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

3.  An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.

Authors:  James C Romero-Masters; Makoto Ohashi; Reza Djavadian; Mark R Eichelberg; Mitchell Hayes; Nicholas A Zumwalde; Jillian A Bristol; Scott E Nelson; Shidong Ma; Erik A Ranheim; Jenny E Gumperz; Eric C Johannsen; Shannon C Kenney
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

4.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.

Authors:  Ryan M Young; Tianyi Wu; Roland Schmitz; Moez Dawood; Wenming Xiao; James D Phelan; Weihong Xu; Laurence Menard; Eric Meffre; Wing-Chung C Chan; Elaine S Jaffe; Randy D Gascoyne; Elías Campo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

5.  Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Authors:  Joseph D Dekker; Daechan Park; Arthur L Shaffer; Holger Kohlhammer; Wei Deng; Bum-Kyu Lee; Gregory C Ippolito; George Georgiou; Vishwanath R Iyer; Louis M Staudt; Haley O Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 6.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

Review 7.  B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Ryan M Young; Arthur L Shaffer; James D Phelan; Louis M Staudt
Journal:  Semin Hematol       Date:  2015-01-15       Impact factor: 3.851

8.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

Review 9.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

Review 10.  New roles for B cell receptor associated kinases: when the B cell is not the target.

Authors:  Phuong-Hien Nguyen; Emanuel Niesen; Michael Hallek
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.